Related Experiment Videos
Mycophenolate mofetil
T M Sievers1, S J Rossi, R M Ghobrial
1Department of Surgery, Center for Liver Diseases and Transplantation, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Pharmacotherapy
|December 17, 1997
Summary
Mycophenolate mofetil, an immunosuppressant, prevents organ transplant rejection by inhibiting lymphocyte proliferation. It is approved for kidney transplants and shows promise for treating various refractory and chronic transplant rejections.
Area of Science:
- Immunology
- Pharmacology
- Transplantation Medicine
Background:
- Mycophenolate mofetil is a prodrug of mycophenolic acid.
- Mycophenolic acid inhibits lymphocyte proliferation by targeting inosine monophosphate dehydrogenase.
- This enzyme is crucial for the de novo synthesis of guanine nucleotides.
Purpose of the Study:
- To summarize the role and efficacy of mycophenolate mofetil in organ transplantation.
- To highlight its current approved indication and potential therapeutic applications.
Main Methods:
- Review of existing studies on mycophenolate mofetil in transplantation.
- Analysis of its mechanism of action and clinical outcomes.
Main Results:
- Mycophenolate mofetil is approved for preventing acute renal allograft rejection with cyclosporine and steroids.
- Studies show efficacy in treating refractory rejection in renal, heart, and liver transplants.
- Potential efficacy in managing chronic transplant rejection is suggested.
Conclusions:
- Mycophenolate mofetil is a valuable immunosuppressant for preventing and treating transplant rejection.
- Its mechanism of action provides a basis for its broad applicability in various transplant settings.